RecruitingNot ApplicableNCT05675345

Physiological Effects of Continuous Negative External Pressure for Acute Hypoxemic Respiratory Failure

Physiological Effects of Continuous Negative External Pressure for Acute Hypoxemic Respiratory Failure: A Pilot Crossover Trial


Sponsor

Columbia University

Enrollment

20 participants

Start Date

Feb 28, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This study is being conducted to evaluate if wearing a non-invasive breathing support device over the chest/abdomen improves markers of breathing in patients with lung injury requiring high-flow oxygen. The breathing support device consists of a plastic shell that sits over the chest and abdomen and connects to a vacuum that helps the chest expand with breathing. This breathing support is known as continuous negative external pressure (CNEP). Study findings will help determine if this breathing support device might be useful for patients with acute hypoxemic respiratory failure (AHRF).


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Age 18 years or older
  • Acute hypoxemic respiratory failure
  • Non-cardiogenic airspace opacities on chest radiograph or computed tomography (CT) scan
  • High-flow nasal cannula (flow ≥ 30 LPM) initiated within last 96 hours (4 days)
  • FiO2 ≥ 40%
  • SpO2 ≥ 92%

Exclusion Criteria26

  • Do-not-intubate order
  • Anatomical factor predisposing to poor fit of cuirass (e.g. severe kyphosis or scoliosis)
  • Use of cuirass precluded, e.g. due to:
  • Clinically prescribed prone positioning
  • Tense ascites
  • Severe abdominal pain
  • Abdominal wound or surgery
  • Pregnancy
  • Agitated delirium
  • Prior intubation during hospital stay
  • Cardiogenic pulmonary edema
  • Exacerbation of asthma or COPD
  • Chronic lung disease, including:
  • Interstitial lung disease
  • Cystic fibrosis
  • Lung mass, lung cancer, or metastasis to the lung
  • Lung transplant recipient
  • Any disease that requires home oxygen
  • Glasgow coma score < 15
  • Chest tube, pneumothorax, or pneumomediastinum
  • Hemodynamic instability (mean arterial pressure < 55 mmHg or norepinephrine-equivalent vasopressor requirement > 0.1mcg/kg/min)
  • Implantable electrical device (e.g. pacemaker, defibrillator, neurostimulator)
  • Unreliable pulse-oximetry tracing
  • Imminent intubation
  • Anticipated lack of patient availability to complete study procedures (e.g. due to planned clinical procedure such as CT scan or dialysis during potential time of study)
  • Attending physician refusal

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEHFNC only

HFNC for 45 minutes, with FiO2 titrated to SpO2 of 90-97%

DEVICEHFNC + CNEP10

HFNC with CNEP of 10 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%

DEVICEHFNC + CNEP20

HFNC with CNEP of 20 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%

DEVICEHFNC + CNEP30

HFNC with CNEP of 30 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%


Locations(1)

Columbia University Irving Medical Center

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05675345


Related Trials